Key facts
- This page summarizes ADAR1 Capital Management, LLC's Form 3/A filing for Acasti Pharma Inc. (GRCE).
- 0 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 11 Jul 2024, 11:16.
ADAR1 Capital Management, LLC - 28 Jun 2024 Form 3/A Insider Report for Acasti Pharma Inc. (GRCE)
- Reporting relationship
- 10%+ Owner
- Issuer ticker
- GRCE
- Reported as of
- 28 Jun 2024
- Net transaction value
- $0
- SEC form
- 3/A
- Accepted by SEC
- 11 Jul 2024, 11:16:42 UTC
- Original report date
- 09 Jul 2024
- Next SEC filing
- 31 Jul 2024
- Source filing
- View source filing
- Reporting owner signature
- ADAR1 Capital Management, LLC, By /s/ Daniel Schneeberger, Manager
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
ADAR1 Capital Management, LLC filed Form 3/A for Acasti Pharma Inc. (GRCE) on 11 Jul 2024.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Official SEC source
View source filing
Ownership activity is grounded in SEC Form 3/A disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ACST
holding
Class A Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 959,571
- Date
- 28 Jun 2024
- Ownership
- By: ADAR1 Partners
- Footnotes
- F1, F2, F3
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ACST
holding
Derivative
Common Warrant (Common Stock)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 28 Jun 2024
- Ownership
- By: ADAR1 Partners
- Underlying class
- Common Stock
- Underlying amount
- 1,268,195
- Exercise price
- $3.00
- Footnotes
- F1, F2, F3, F5
ACST
holding
Derivative
Pre-Paid Warrant (Common Stock)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 28 Jun 2024
- Ownership
- By: ADAR1 Partners
- Underlying class
- Common Stock
- Underlying amount
- 913,631
- Exercise price
- $0.000100
- Footnotes
- F1, F2, F3, F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 5 footnotes
Footnote F1
ADAR1 Capital Management GP, LLC is the general partner of ADAR1 Partners, LP ("ADAR1 Partners").
Footnote F2
ADAR1 Capital Management, LLC ("ADAR1 Capital"), an entity owned and controlled by Dr. Daniel Schneeberger, owns voting and investment control with respect to the shares held by ADAR1 Partners, LP. Because of the relationship between ADAR1 Partners and ADAR1 Capital, ADAR1 Capital may be deemed to beneficially own the shares held directly by ADAR1 Partners.
Footnote F3
For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.
Footnote F4
Pursuant to a Pre-Funded Common Stock Purchase Warrant, ADAR1 Partners may purchase up to 913,631 shares of Issuer's Common Stock, exercisable until fully filled.
Footnote F5
Pursuant to a Common Stock Purchase Warrant, ADAR1 Partners may purchase up to 1,268,195 of Issuer's Common Stock.